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Objective: This study used a decision-analytic framework to assess the cost-effectiveness of 
brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among 
adults with schizophrenia from a US payer perspective.
Methods: An economic model was developed to assess patients with stable schizophrenia 
initiating treatment with brexpiprazole (1–4 mg), cariprazine (1–6 mg), or lurasidone (40–80 
mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due 
to relapse, adverse events, or other reasons. Patients who discontinued due to relapse or adverse 
events were assumed to have switched to other therapy, and those who discontinued due to 
other reasons were assumed to have received no therapy. Primary outcomes were incremental 
cost per relapse avoided and hospitalization avoided, and the secondary outcome was cost per 
quality-adjusted life-year (QALY) gained. Sensitivity and scenario analyses were also conducted.
Results: Brexpiprazole was associated with the highest per-patient clinical effectiveness 
(avoided relapses 0.637, avoided hospitalizations 0.719, QALYs 0.707) among comparators, 
followed by cariprazine (avoided relapses 0.590, avoided hospitalizations 0.683, QALYs 0.683) 
and lurasidone (avoided relapses 0.400, avoided hospitalizations 0.536, QALYs 0.623). Annual 
per-patient health-care costs were lowest for brexpiprazole ($20,510), followed by cariprazine 
($22,282) and lurasidone ($25,510). Brexpiprazole was the least costly and most effective 
treatment strategy for all outcomes. Results were sensitive to relapse rates and daily cost of 
brexpiprazole. Limitations include data principally obtained from drug-specific randomized 
withdrawal studies and lack of direct-comparison trials.
Conclusion: This analysis evaluated brexpiprazole treatment for the reduction of schizophrenia 
relapses and hospitalizations over a 1-year period compared to other recently available branded 
antipsychotics, and excluded generic antipsychotic treatments. Brexpiprazole treatment may 
lead to clinical benefits and medical cost savings, and provides a cost-effective treatment option 
for patients relatively to other branded second-generation antipsychotics.
Keywords: schizophrenia, cost-effectiveness, relapse prevention, cost-benefit, indirect analysis, 
event avoided, hospitalization avoided, brexpiprazole
Introduction
Schizophrenia is a complex and disabling mental disorder characterized by delusions, 
hallucinations, disorganized speech and behavior, negative symptoms, cognitive 
impairment, and other symptoms that contribute to social and occupational dysfunc-
tion.1 The disorder affects approximately 1.1% of adults in the USA.2 The economic 
burden of schizophrenia in the US is substantial: estimated at $156 billion in 2013.3 
Schizophrenia-relapse rates are high, and further contribute to the economic burden 
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of the disorder. Acher-Svanum et al found that total annual 
direct mental health-care costs were about three times higher 
among persons with schizophrenia who experienced relapses 
in the 6 months prior to the study compared to patients who 
did not experience relapses in that period.4
The goals of schizophrenia treatment have evolved over 
the last several decades, and focus on increasing quality of 
life (QoL) and functioning and striving for remission.5–7 
Guidelines recommend psychosocial interventions incorpo-
rated into all phases of patient management, with the goal of 
minimizing stress and maximizing patient functioning.6 The 
American Psychiatric Association practice guidelines sup-
port the use of programs, such as community interventions 
(eg, Program for Assertive Community Treatment, family 
interventions, supported employment, cognitive behavioral 
therapy, social skills training, and programs of early inter-
vention to delay relapse).6 The association recommends 
antipsychotic agents as the mainstay of treatment for schizo-
phrenia; however, variance in pharmacological profiles create 
clinically relevant variability in tolerability and efficacy.8 
Typical antipsychotics (ie, first-generation antipsychotics) are 
antagonists at dopamine D
2
 receptors and effective against 
psychotic symptoms. However, these agents have a high rate 
of motoric adverse events (AEs), such as drug-induced par-
kinsonism and tardive dyskinesia, at therapeutic doses. Atypi-
cal antipsychotic agents (ie, second-generation antipsychotics 
[SGAs]) available in the US include clozapine, risperidone, 
olanzapine, quetiapine, ziprasidone, aripiprazole, lurasidone, 
paliperidone, iloperidone, cariprazine, and asenapine. These 
atypical antipsychotics differ from one another in their toler-
ability profile. Although atypical antipsychotics may have 
reduced risk of motoric side effects, there is evidence that 
demonstrates variable risk of weight gain, diabetes, hyper-
lipidemia, and cardiovascular complications.
Although antipsychotic medications can manage the 
symptoms of schizophrenia effectively and help patients to 
achieve remission, relapses are common.9 In addition, dis-
continuation rates for antipsychotic medications are high in 
both clinical trial and real-world settings. For example, in the 
US Clinical Antipsychotic Trials of Intervention Effective-
ness study,10 the overall discontinuation rate over 18 months 
for patients with chronic schizophrenia taking antipsychot-
ics was 74%, and in a 3-year European observational study 
discontinuation rates were 34%–66%.11
Poor tolerability and side effects of antipsychotics are 
among the primary reasons for premature treatment discon-
tinuation, resulting in inadequate symptom resolution and 
an increased risk of relapse.12,13 Therefore, additional toler-
able treatment options are needed. Brexpiprazole is an SGA 
approved by the US Food and Drug Administration (FDA) 
in July 2015 as monotherapy for schizophrenia in adults. The 
efficacy of brexpiprazole in schizophrenia was demonstrated 
in two 6-week, randomized, double-blind, placebo-controlled, 
fixed-dose clinical trials.14,15 Brexpiprazole has demonstrated 
a low incidence of sedating or activating AEs, a low rate of 
long-term metabolic effects, and moderate weight gain.14–16 
The efficacy of brexpiprazole was also demonstrated in a 
randomized-withdrawal, double-blind, placebo-controlled, 
52-week maintenance study,17 which showed a reduction in 
risk of relapse of 71% vs placebo over 1 year and an incidence 
of AEs that was comparable to placebo.
Evidence of efficacy and tolerability remains important 
in the evaluation and comparison of available therapies; how-
ever, it is also important to determine their cost-effectiveness, 
given limitations on health-care spending. In the absence of 
head-to-head studies, indirect comparisons to evaluate the 
cost-effectiveness of treatments for schizophrenia can assist 
in health-care decision-making. This study used a decision-
analytic framework to assess the cost-effectiveness of brexpipra-
zole in schizophrenia for reducing relapses and hospitalizations 
among adults with schizophrenia from a US payer perspective.
Evaluating the cost-effectiveness of newly available 
branded treatments in schizophrenia can shape policies 
concerning treatment coverage and reimbursement. Decision 
makers emphasize the need for more timely information.18 
In the US, the majority of oral antipsychotics are available 
as generic products. Given increasing pressures to manage 
health-care costs, it is expected that generic-drug utilization 
is generally prioritized over the use of branded treatments. 
For policy makers evaluating new branded treatments for 
formulary placement, an appropriate pharmacoeconomic 
analysis would involve comparisons of newly available and 
existing branded treatments.
Methods
Model overview
A decision-analytic model was developed to evaluate a hypo-
thetical cohort of adult patients with stable schizophrenia 
initiating treatment with brexpiprazole, cariprazine, or lurasi-
done. Lurasidone and cariprazine were selected as compara-
tors because they are the most recently FDA-approved SGAs 
and long-term prevention studies on them were comparable 
to those on brexpiprazole in terms of patient population, 
trial design, and end points. In the long-term maintenance 
trials, all patients were stabilized before entering a random-
ized, double-blind phase for at least 12 weeks. Additionally, 
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relapse definitions were comparable across trials. Modeled 
treatment doses were based on those evaluated in long-term 
prevention studies from which clinical events were derived: 
brexpiprazole (1–4 mg), cariprazine (1–6 mg), and lurasidone 
(40–80 mg). It was assumed that patients remained adherent 
to treatment during treatment-initiation and -switch periods.
Model outputs are reported over a 1-year model time 
horizon, which was chosen to be consistent with the clinical 
trial duration period. It is clinically relevant to model schizo-
phrenia outcomes within 1 year, because clinical effectiveness 
and treatment discontinuation are typically seen within this 
period and data beyond 1 year are limited.10,19 Due to the 
length of the time horizon, discounting (ie, translating future 
costs and benefits into present-day values) was not applied.
The model incorporated direct costs related to drug 
acquisition, AE treatment, relapse-related treatment, and 
patient monitoring. All costs are reported in 2016 US$. 
Clinical events were estimated from long-term relapse trials 
(efficacy) and acute trials (AEs) for each model compara-
tor. Cost-effectiveness was evaluated for primary outcomes 
of incremental cost per relapse avoided and cost per hospi-
talization avoided and the secondary outcome of cost per 
quality-adjusted life-year (QALY) gained. The model was 
programmed using Microsoft Excel 2010.
Model population and structure
The model evaluated a hypothetical cohort of adults with 
stable- phase schizophrenia consistently with patients 
enrolled in long-term prevention studies of brexpiprazole,17 
cariprazine,20 and lurasidone.21 Initially, patients entered the 
model and were treated with brexpiprazole, cariprazine, or 
lurasidone (Figure 1). Following treatment initiation, patients 
remained on therapy for the full year or discontinued treat-
ment after 6 months due to relapse/lack of treatment effi-
cacy, AEs, or other reasons (including cost of medication, 
nonadherence, patient preference, or unknown). Because the 
median time to discontinuation in the brexpiprazole study17 
was 169 days, the use of 6 months (approximately 183 days) 
was unlikely to bias model results.
Patients who discontinued due to relapse/lack of treat-
ment efficacy or AEs were assumed to switch to composite 
therapy, which included generic SGAs (ie, olanzapine, ris-
peridone, quetiapine, ziprasidone, and aripiprazole). Patients 
who discontinued due to other reasons were assumed to 
receive no additional therapy. For patients who switched 
to composite therapy, it was assumed that the likelihood of 
receiving any one of the therapies was the same. Therefore, 
rates of relapse and AEs were calculated as averages for 
the composite therapies. Although patients who switched 
to composite therapy could experience relapse or AEs, 
they were assumed to continue treatment throughout the 
remainder of the year.
Model estimation
Clinical inputs
Key clinical inputs were derived from 52-week mainte-
nance relapse studies for brexpiprazole17 and cariprazine,20 
a 28-week maintenance relapse study for lurasidone,21 and 
published reports and package inserts (PIs) for SGAs used for 
composite therapy. Clinical parameters included in the model 
were rates of treatment discontinuation, relapse/impending 
relapse, and AEs (Tables 1–3).
Figure 1 Model structure.
Notes: aTreatment included brexpiprazole, lurasidone, and cariprazine; bComposite therapy: olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole
Abbreviation: AEs, adverse events.
Continue treatment Continue therapy Relapse
No relapse
No relapse
No relapse
No relapse
Relapse
Relapse
Relapse
Composite therapyb
No therapy
Composite therapyb
Treatmenta
Patients with schizophrenia
at stable phase
Discontinued due to relapse/lack of efficacy
Discontinued due to AEs
Discontinued due to other reasons
Before discontinuation: 6 months After discontinuation: 6 months
1-year time horizon
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In the absence of direct-comparison trials of treatments, an 
indirect comparison was conducted to determine differences 
in treatment discontinuation and relapse. Because treatments 
were all compared to placebo in their long-term maintenance 
trials, this indirect comparison used placebo as the common 
comparator to obtain model-efficacy values. Derived rates 
were calculated for treatment discontinuation, which allowed 
a more accurate comparison of clinical events across compara-
tor cohorts. In general, derived rates were calculated as the 
product between the relative clinical rate within a trial (active 
vs respective placebo) and a pooled placebo clinical rate (see 
Supplementary material for calculation details). The probabili-
ties of relapse at 6 months for treatments in composite therapy 
are presented in Table 1. Because relapses vary in severity, the 
model assumed that 77.3% of relapses resulted in an inpatient 
hospitalization and 22.7% were treated on an outpatient basis.22
Adverse events
The model assumed that patients could experience six types 
of potential treatment-emergent AEs: akathisia, extrapyrami-
dal symptoms, glucose abnormalities (fasting glucose crite-
ria), lipid abnormalities (fasting total cholesterol criteria), 
sedation, and weight gain (≥7% weight gain from baseline; 
Table 2). AE rates were pooled as needed,23 and absolute 
rates of AEs across comparator trials were used.24,25 AE rates 
for composite-therapy treatments were obtained from the 
product labels. Sedation as a unique AE identifier was not 
reported in the lurasidone PI; therefore, a weighted average 
was calculated using published data.26
Economic inputs
Cost parameters were derived from the literature, and 
included schizophrenia-care costs related to drug acqui-
sition, relapse, treatment discontinuation/switching, and 
Table 1 Probability of treatment discontinuation and relapse at 
6 months
Mean SEa Source
Probability of treatment discontinuation at 6 months due to 
relapse
Brexpiprazole 16.0% 0.8% Fleischhacker et al17
Lurasidone 30.9% 1.5% Tandon et al21
Cariprazine 18.5% 0.9% Durgam et al20
Probability of treatment discontinuation at 6 months due to 
AEs
Brexpiprazole 23.3% 1.2% Fleischhacker et al17
Lurasidone 7.8% 0.4% Tandon et al21
Cariprazine 8.2% 0.4% Durgam et al20
Probability of treatment discontinuation at 6 months due to 
other reasonsb
Brexpiprazole 16.5% 0.8% Fleischhacker et al17
Lurasidone 32.0% 1.6% Tandon et al21
Cariprazine 18.8% 0.9% Durgam et al20
Probability of relapse in composite arm
Composite therapy 14.9%b NA Calculation
Olanzapine 4.0% 0.2% Beasley et al43
Risperidone 15.0% 0.8% Csernansky et al39
Quetiapine 15.4% 0.8% Peuskens et al44
Ziprasidone 16.3% 0.8% Arato et al45
Aripiprazole 23.7% 1.2% Pigott et al46
Notes: aAll SEs assumed to be 5% of the mean; bother reasons included cost of 
medication, nonadherence, patient preference, or unknown.
Abbreviation: NA, not applicable.
Table 2 Adverse-event rates
Treatment Akathisia,  
mean (SE)
EPS,  
mean (SE)
Glucose  
abnormalities,a 
mean (SE)
Lipid  
abnormalities,b 
mean (SE)
Sedation,  
mean (SE)
Weight  
gain ≥7%,  
mean (SE)
Source
Brexpiprazole 6.9% (0.3%) 14.0% (0.7%) 3.4% (0.2%) 2.3% (0.1%) 2.7% (0.1%) 10.2% (0.5%) Rexulti PI24
Lurasidone 11.5% (0.6%) 11.5% (0.6%) 9.6% (0.5%) 5.7% (0.3%) 10.0% (0.5%) 4.8%(0.2%) Latuda PI25
Citrome26
Cariprazine 11.0% (0.6%) 16.0%c (0.8%) 8.4% (0.4%) 3.4%d (0.2%) 4.0% (0.2%) 3.0% (0.2%) Vraylar summary review47
Durgam et al48
Composite 
therapy
7.2% (0.4%) 14.0% (0.7%) 5.3% (0.3%) 6.4% (0.3%) 15.4% (0.8%) 14.8% (0.7%) Calculation (mean rate 
across SGAs)
Olanzapine 8.7% 24.2% 2.2% 2.8% 29.9%e 22.2% Zyprexa PI49
Risperidone 10.0% 15.1%f 0.3% 4.6% 8.2% 10.8% Risperdal PI50
Quetiapine 1.2% 3.5%g 2.4% 18.0% 18.0%e 23.0% Seroquel PI51
Ziprasidone 8.0% 14.0% 17.6% 3.9% 14.0%e 9.7% Geodon PI52
Aripiprazole 8.0% 13.0% 3.8% 2.5% 7.0%h 8.1% Abilify PI53
Notes: Absolute rates (not placebo-adjusted). aFasting glucose criteria: normal to high (<100–≥126 mg/dL). For lurasidone, the normal to high criterion was ≥160 mg/dL; 
for risperidone, the normal–high cutoff was <140 mg/dL to ≥200 mg/dL. bFasting total cholesterol criteria: normal–high (<200–≥240 mg/dL). For lurasidone, the normal–high 
criterion was ≤200 mg/dL; for quetiapine, the criterion was ≥240 mg/dL. cAny EPS, excluding akathisia/restlessness. dWeighted average calculated based on total cholesterol 
(>1.3 × ULN [200 mg/dL]) rates from three treatment arms: 1.5, 3, and 4.5 mg. eNo sedation data reported. Somnolence rate was used. fNo EPS data reported. Parkinsonism 
(includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia, bradykinesia, hypokinesia) rate from two treatment arms: 2–8 mg and 
>8–16 mg/day. gIncludes restless and extrapyramidal disorder. hData from pooled incidence (rounded) of adverse reactions that occurred during acute therapy (up to 6 weeks 
in schizophrenia and up to 3 weeks in bipolar mania).
Abbreviations: EPS, extrapyramidal symptoms; PI, package insert; SGAs, second-generation antipsychotics; ULN, upper limit of normal.
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treatment costs for AEs (Table 3). Costs are reported as 2016 
US$, and where applicable are inflated to 2016 US$ using 
the medical care component of the consumer price index.27 
The model also included the cost of treatment-related 
monitoring, considered the office-visit cost of monitoring 
per outpatient,27 and assumed that a treated patient would 
require one monitoring visit per month. An additional cost 
of switching treatments was also applied.19,27 If patients 
discontinued treatment due to other reasons, the analysis 
did not assign any composite therapy, and thus no additional 
treatment-related costs applied. Lastly, the costs of treating 
relevant AEs (Table 3) were assumed to occur only within 
a 6-week period.
Utility inputs
The model used health-state utilities to estimate the impact 
of treatments on patients’ QoL. Utility weights were obtained 
from published QoL data among patients with stable schizo-
phrenia.28,29 Utilities associated with relapse with or without 
hospitalization and AEs were derived from the utility value 
from stable schizophrenia. Mean (SE) health-state-utility 
values were 0.88 (4.4%) for stable disease, 0.53 (2.7%) for 
relapse with hospitalization, and 0.74 (3.7%) for relapse 
without hospitalization.28,29 Mean (SE) utility decrements 
associated with AEs were 0.090 (0.005) for akathisia,28 0.099 
(0.005) for extrapyramidal symptoms,28 0.067 (0.003) for glu-
cose abnormalities,30 0.099 (0.005) for lipid abnormalities,31 
Table 3 Estimated cost inputs
Estimate SE Source
Treatment-related costs
Monitoring $95.19 $4.76 US Bureau of Labor Statistics27
Treatment switch $282.98 $14.15 Citrome et al19
Relapse-treatment costs
Inpatient $32,495.41 $1,624.77 Agency for Healthcare Research and Quality54
Outpatient $657.69 $32.88 Park and Kuntz55
Adverse events
Akathisia $232.94 $11.65 Citrome et al19
US Bureau of Labor Statistics27EPS $242.01 $12.10
Glucose abnormalities $75.65 $3.78
Lipid abnormalities $173.39 $8.67
Sedation $282.98 $14.15
Weight gain ≥7% $830.19 $41.51
Treatment-acquisition costs (WAC)
Brexpiprazole
4 mg ($/day)
$31.16 $1.56 Truven Health Analytics56
Lurasidone
40 mg ($/day)
60 mg ($/day)
80 mg ($/day)
$30.73
$30.73
$30.73
$1.54
$1.54
$1.54
Cariprazine
1.5 mg ($/day)
3.0 mg ($/day)
4.5 mg ($/day)
6.0 mg ($/day)
$33.54
$33.54
$33.54
$33.54
$1.68
$1.68
$1.68
$1.68
Composite therapy
Olanzapine
10 mg ($/day)
$18.44 $0.92
Risperidone
4 mg ($/day)
$23.81 $1.19
Quetiapine
200/300 mg ($/day)
$18.75 $0.94
Ziprasidone
40/60 mg ($/day)
$16.24 $0.81
Aripiprazole
30 mg ($/day)
$42.05 $2.10
Notes: All costs reported in 2016 US$.
Abbreviations: EPS, extrapyramidal symptoms; WAC, wholesale-acquisition cost.
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0.084 (0.004) for sedation,32 and 0.036 (0.002) for weight gain 
≥7%.32 Because utility-weight decrements were not avail-
able for glucose abnormalities, the utility for symptomatic 
nonsevere hypoglycemia in patients with diabetes was used.
Analysis
Total direct schizophrenia-related health-care costs, incre-
mental costs, and clinical improvement (ie, number of 
relapses and hospitalizations avoided) were estimated for 
each treatment in the model. Incremental cost:effectiveness 
ratios (ICERs) were expressed as cost per relapse avoided, 
cost per hospitalization avoided, and cost per QALY gained. 
These outcomes were calculated at the end of 1 year as the 
ratio of the difference between the cost of schizophrenia-
related care in patients receiving brexpiprazole vs alternative 
treatment and the difference in the number of patients avoid-
ing relapses or hospitalizations, respectively.
Sensitivity analyses
One-way sensitivity analyses were conducted to quantify the 
impact of change in individual model parameters on model 
outcomes. All clinical and economic parameters were varied 
by 1 SD within a predefined statistical distribution of the 
base-case values to determine which variables would have 
the greatest impact on the incremental net monetary benefit 
(NMB).
To assess uncertainty in the cost-effectiveness analysis, a 
probabilistic sensitivity analysis (PSA) was also conducted 
using a second-order Monte Carlo simulation. The PSA 
was performed by simultaneously drawing from appropriate 
distribution functions for all model parameters according 
to their means and SEs (Tables 1–3). All rates were varied 
using β-distribution and costs varied using γ-distribution. 
The PSA was repeated 1,000 times, and results reporting 
the NMB for different willingness-to-pay (WTP) thresh-
olds ($0–$100,000) per selected outcome (avoided relapse, 
avoided hospitalization, and QALYs) were used to evaluate 
the robustness of model outcomes.
Scenario analyses were conducted to understand further 
the impact of model estimate assumptions for AEs and drug 
costs related to generic options in composite therapy. AE 
rates were incorporated into the model using absolute esti-
mates from comparator trials. To assess the impact of using 
derived rates of AEs in the model, a scenario analysis was 
conducted. Wholesale-acquisition-cost branded pricing was 
used to estimate drug costs for treatments in the composite-
therapy arm. However, given that treatments are generic, a 
second-scenario analysis using retail pricing from national 
wholesaler Costco33 was deemed appropriate to assess the 
impact of lower-cost drug costs.
Results
In a hypothetical cohort of 1,000 patients, the model esti-
mated that brexpiprazole was the dominant treatment strategy 
compared to cariprazine and lurasidone over the 1-year time 
horizon (Table 4). In terms of clinical outcomes, treatment 
with brexpiprazole was associated with higher effectiveness 
(all outcomes shown per patient; avoided relapses 0.637, 
avoided hospitalizations 0.719, QALYs 0.707), followed by 
cariprazine (avoided relapses 0.590, avoided hospitalizations 
0.683, QALYs 0.683) and lurasidone (avoided relapses 0.400, 
avoided hospitalizations 0.536, QALYs 0.623). Brexpipra-
zole was also associated with lower total schizophrenia-
related health-care costs per patient ($20,510), followed by 
cariprazine ($22,282) and lurasidone ($25,510). In the ICE 
analyses, brexpiprazole was the dominant (ie, less costly and 
Table 4 Base-case cost-effectiveness analysis
Brexpiprazole Lurasidone Cariprazine
Total annual cost per patient  
(medical + pharmacy)
$20,510 $25,510 $22,283
Relapses 0.363 0.600 0.410
Relapses avoided 0.637 0.400 0.590
Hospitalizations 0.281 0.464 0.317
Hospitalizations avoided 0.719 0.536 0.683
QALYs 0.707 0.623 0.683
Change in total cost
-$1,772 $3,227 Reference
Change in avoided relapses 0.047 –0.191 Reference
Change in hospitalizations avoided 0.036 –0.147 Reference
Change in QALYs 0.025 –0.060 Reference
ICER per avoided relapse Dominant Dominated Reference
ICER per hospitalization avoided Dominant Dominated Reference
ICER per QALY Dominant Dominated Reference
Abbreviations: ICER, incremental cost:effectiveness ratio; QALY, quality-adjusted life-year.
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more effective) treatment strategy compared with lurasidone 
and cariprazine for all ICERs (Table 4). A cost-effectiveness 
plane displaying results is presented in Figure 2.
Sensitivity analyses
Figures S1 and S2 show the results of the one-way sensitivity 
analyses comparing brexpiprazole vs lurasidone and carip-
razine, respectively, for the ten most influential variables at 
a WTP threshold of $30,000 per relapse avoided. As shown 
in the tornado diagram, when brexpiprazole was compared 
to lurasidone (Figure S1), the model parameters with the 
largest impact on the incremental NMB were the 6-month 
discontinuation probability due to relapse for brexpipra-
zole, 6-month discontinuation probability due to relapse 
for lurasidone, and daily cost of brexpiprazole. Results of 
one-way sensitivity analyses with the same WTP ($30,000) 
per relapse-related hospitalization avoided and QALYs 
showed similar results. When brexpiprazole was compared 
to cariprazine (Figure S2), the results were consistent with 
the comparison of brexpiprazole and lurasidone. Results of 
the PSA using a WTP range of $0–$100,000 per avoided 
relapse, per avoided hospitalization, and per QALY are 
shown in Table S1. Based on 1,000 simulations, all results 
indicated that brexpiprazole was associated with lower cost 
and better effectiveness, yielding the highest NMB among 
all comparators.
Scenario analysis
Calculated derived rates of AEs from the first-scenario analy-
sis are presented in Table S2. In this scenario, brexpiprazole 
was also the dominant treatment strategy compared with 
lurasidone and cariprazine for all ICERs evaluated (Table S3). 
In the second-scenario analysis using retail pricing from 
Costco33 for the composite treatments, cost-effectiveness 
results were similar to the base-case analysis (Table S4). For 
each treatment, the total annual cost per patient was slightly 
lower compared to results reported in the base-case scenario. 
Results from these two scenario analyses showed consistent 
findings with the base-case analyses.
Discussion
Schizophrenia poses substantial human and economic bur-
den, and despite the availability of several SGAs, it remains 
a difficult disorder to treat effectively. A recent study34 found 
that schizophrenia was one of the three most burdensome 
diseases on an annual per patient basis, estimated at $46,537 
in 2014 US$. Relapses have a significant impact on the 
economic burden of schizophrenia, with relapsed patients 
incurring three to four times higher health-care costs than 
nonrelapsed patients, driven primarily by the costs of hospi-
talization for relapsed patients.4,35
Brexpiprazole is a recently approved SGA treatment option 
for adults with schizophrenia. To our knowledge, this is the 
first cost-effectiveness analysis to compare brexpiprazole with 
other branded SGAs in reducing schizophrenia relapses and 
hospitalizations. Results of the base-case cost-effectiveness 
analyses showed that brexpiprazole was the dominant treat-
ment strategy compared with lurasidone and cariprazine for all 
outcomes assessed. Although this is the only cost-effectiveness 
analysis of brexpiprazole compared to lurasidone and caripra-
zine we are aware of, the cost-effectiveness of lurasidone has 
been explored in previous  studies;36–38 however, these models 
included different populations, comparators, inputs, assump-
tions, and time horizons, making comparison across studies 
difficult. Model results should be considered in light of limita-
tions. The analysis was based on data from placebo-controlled 
trials; as such, results of this analysis may not be generalizable 
to treatment provided under real-world conditions. In addition, 
the probability of relapse for the composite therapy risperidone 
was not derived from a randomized, placebo-controlled with-
drawal study, as one was not conducted by the manufacturer. 
Therefore, probability of relapse came from a maintenance 
study of risperidone vs haloperidol that did not involve a period 
of stabilization followed by medication withdrawal.39
The use of observed AE rates from short-term acute-
schizophrenia trials due to lack of long-term comparable 
comparator data could be another study limitation. However, 
we employed an indirect-comparison method and derived 
placebo-adjusted rates in scenario analyses. Both scenario and 
sensitivity analyses suggested that those rates were not identi-
fied as major model drivers and had only a minimal impact on 
the cost-effectiveness results. Furthermore, incorporation of 
the short-term cost of treating AEs, such as change in glucose, 
cholesterol, and weight only reflects short-term treatment 
costs; however, the potential long-term risks of diabetes, 
obesity, and complications, such as cerebrovascular accident 
and cardiovascular disease, are not included in the analysis 
and warrant consideration in a longer-term evaluation.
The model included only the treatment doses that were 
evaluated in the long-term prevention trials; therefore, effi-
cacy at higher doses for lurasidone was not evaluated and 
may affect findings. In the long-term, placebo-controlled 
maintenance trial of lurasidone, patients were randomized to 
40–80 mg/day lurasidone or placebo.21 However, the PI for 
lurasidone recommends a dose of up to 160 mg per day,25 and 
some patients who have an inadequate response to doses up to 
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Figure 2 Cost-effectiveness plane per patient.
Notes: (A) Cost-effectiveness per relapse avoided; (B) cost-effectiveness per hospitalization avoided; (C) cost-effectiveness per QALY gained.
Abbreviation: QALY, quality-adjusted life-year.
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80 mg/day will require higher-dose treatment.40 As noted by 
Citrome,41 the Tandon et al21 study had some different findings 
between US and non-US study sites, which may have further 
limited the effect size observed in this study relative to other 
similar studies of SGAs. Furthermore, given the objective of 
the study, this analysis considered only the branded agents 
that are available in the US for which a generic formulation 
is not available and where supportive long-term prevention 
trials have been published.
Finally, this cost-effectiveness analysis takes a US payer 
perspective, and thus results may not be generalizable to other 
populations and/or countries in which health-care-resource 
utilization and clinical practice may be different. This model 
also assumed that 77.3% of all relapses resulted in an inpa-
tient hospitalization and the remaining relapses (22.7%) were 
treated on an outpatient basis.22 This assumption was based 
on a study conducted in England, which may not reflect US 
treatment patterns. To account for the impact of various 
parameter estimates on the model results, we conducted both 
deterministic and probabilistic sensitivity analyses, which 
showed consistent results that brexpiprazole dominated 
lurasidone and cariprazine. As noted by Meltzer, attention is 
essential to important methodological issues in constructing 
cost-effectiveness analysis of treatments in schizophrenia.42 
There are key issues in developing a cost-effectiveness model 
in schizophrenia that includes perspective, benefits, and 
future costs. Due to limited available long-term data across 
comparators, the current model framework was deemed 
appropriate to evaluate short-term relapse outcomes.
Conclusion
These findings suggest that treatment with brexpiprazole may 
lead to clinical benefits and medical cost savings. Brexpipra-
zole treatment resulted in fewer relapses and hospitalizations, 
lower total cost of treatment, and higher QoL compared to 
cariprazine and lurasidone. Given the heterogeneity of treat-
ment response in schizophrenia, health plans may consider 
making multiple treatment options available, and brexpipra-
zole offers a cost-effective treatment option.
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Supplementary materials
Figure S1 One-way sensitivity analysis for avoided relapses using $30,000 as the WTP threshold (brexpiprazole vs lurasidone)
Abbreviations: WAC, whole acquisition cost; WTP, willingness to pay. 
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Figure S2 One-way Sensitivity analysis for avoided relapses using $30,000 as the WTP threshold (brexpiprazole vs cariprazine)
Abbreviations: WAC, whole acquisition cost; WTP, willingness to pay.
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Discontinuation (Relapse) - Cariprazine at 6 months
Discontinuation (Relapse) - Brexpiprazole at 6 months
Daily cost - Brexpiprazole
Hospitalization at 6 months - Cariprazine  (%)
Hospitalization at 6 months - Brexpiprazole (%)
Daily cost - Cariprazine 1.5 mg WAC price
Daily cost - Cariprazine 3.0 mg WAC price
Daily cost - Cariprazine 4.5 mg WAC price
Daily cost - Cariprazine 6.0 mg WAC price
Discontinuation (Other) - Brexpiprazole at 6 months
Incremental net monetary benefit  
One-way sensitivity analysis Low input High input
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Table S1 Mean probabilistic sensitivity analysis results
Outcome: relapses avoided per patient
Total annual cost per patient  
(medical + pharmacy costs)
Relapses avoided per 
patient
Net monetary 
benefit
Rank
Brexpiprazole $20,457 0.707 $50,283 1
Cariprazine $22,254 0.683 $46,021 2
Lurasidone $25,457 0.623 $36,814 3
Outcome: relapse-related hospitalization avoided per patient
Total annual cost per patient  
(medical + pharmacy costs)
Relapse-related 
hospitalization avoided 
per patient
Net monetary 
benefit
Rank
Brexpiprazole $18,940 0.719 $52,978 1
Cariprazine $21,200 0.683 $47,143 2
Lurasidone $23,929 0.536 $29,663 3
Outcome: QALYs per patient
Total annual cost per patient  
(medical + pharmacy costs)
QALYs per patient Net monetary 
benefit
Rank
Brexpiprazole $20,504 0.706 $50,146 1
Cariprazine $22,311 0.683 $45,894 2
Lurasidone $25,549 0.623 $36,706 3
Abbreviation: QALY, quality-adjusted life-year.
Table S2 Scenario analysis: derived rates of adverse events
Treatment Akathisia
mean 
EPS
mean 
Glucose 
abnormalitiesa
mean
Lipid 
abnormalitiesb
mean
Sedation
mean 
Weight  
gain ≥7%
mean 
Source
Brexpiprazole 5.56% 11.88% 6.82% 4.21% 11.33% 6.63% Rexulti PI1
Lurasidone 14.24% 13.67% 7.66% 4.55% 7.77% 3.87% Latuda PI2
Citrome 20123
Cariprazine 10.19% 14.82%c 8.14% 3.85% 3.36%d 7.99% Vraylar Medical  
Reviews4
Durgam 20145
Composite therapy 7.8% 13.4% 2.7% 4.2% 13.8% 21.2% Calculation (mean  
rate across SGAs)
Olanzapine 4.52% 15.19% 1.70% 3.09% 10.72%e 38.48% Zyprexa PI6
Risperidone 17.34% 18.93%f 1.51% 4.50% 23.68% 19.33% Risperdal PI7
Quetiapine 0.79% 4.53%g 4.52% 7.12% 12.93%e 22.17% Seroquel PI8
Ziprasidone 5.94% 17.60% 3.01% 3.95% 11.49%e 12.55% Geodon PI9
Aripiprazole 10.40% 10.90% 2.78% 2.37% 10.05%h 13.30% Abilify PI10
Notes: Rates of adverse events are absolute rates (not placebo-adjusted). aFasting glucose criteria: Normal to high (<100 to >126 mg/dL). For lurasidone, the normal to high 
criterion was ≥160 mg/dL; for risperidone, the normal to high cutoff was <140 mg/dL to ≥200 mg/dL. bFasting total cholesterol criteria: Normal to high (<200 mg/dL to ≥240 
mg/dL). For lurasidone, the normal to high criterion was <200 mg/dL; for quetiapine, the criterion was ≥240 mg/dL. cAny EPS excluding akathisia/restlessness. dWeighted 
average was calculated based on total cholesterol (>1.3 times ULN [200 mg/dL]) rates from 3 treatment arms: 1.5 mg, 3 mg, and 4.5 mg. eNo sedation data were reported. 
Somnolence rate was used. fNo EPS data were reported. Parkinsonism (includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia, 
bradykinesia, hypokinesia) rate from 2 treatment arms: 2–8 mg and >8–16 mg/day. gIncludes restless and extrapyramidal disorder. hData from pooled incidence, rounded to 
the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania).
Abbreviations: AE, adverse event; EPS, extrapyramidal symptoms; PI, package insert; SGA, second-generation antipsychotic; ULN, upper limit of normal.
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Table S3 Scenario analysis: results of cost-effectiveness analysis using derived AE rates
Brexpiprazole Lurasidone Cariprazine
Total annual cost per patient (medical + pharmacy costs) $20,516 $25,519 $22,349
Relapses 0.363 0.600 0.410
Avoided relapses 0.637 0.400 0.590
Hospitalizations 0.281 0.464 0.317
Avoided hospitalizations 0.719 0.536 0.683
QALYs 0.698 0.624 0.684
Change in total cost $1,833 $3,170 Reference 
Change in avoided relapses 0.047 –0.191 Reference 
Change in avoided hospitalizations 0.036 –0.147 Reference 
Change in QALYs 0.014 –0.060 Reference 
ICER per avoided relapse Dominant Dominated Reference
ICER per avoided hospitalization Dominant Dominated Reference
ICER per QALY Dominant Dominated Reference
Abbreviations: AE, adverse event; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Table S4 Scenario analysis: results of cost-effectiveness analysis using generic drug costs for treatments in composite therapy arm
Brexpiprazole Lurasidone Cariprazine
Total annual cost per patient (medical + pharmacy costs) $18,931 $23,955 $21,210
Relapses 0.363 0.600 0.410
Avoided relapses 0.637 0.400 0.590
Hospitalizations 0.281 0.464 0.317
Avoided hospitalizations 0.719 0.536 0.683
QALYs 0.707 0.623 0.683
Change in total cost
-$2,279 $2,745 Reference
Change in avoided relapses 0.0467 -0.191 Reference
Change in avoided hospitalizations 0.036 -0.147 Reference
Change in QALYs 0.0245 -0.060 Reference
ICER per avoided relapse Dominant Dominated Reference
ICER per avoided hospitalization Dominant Dominated Reference
ICER per QALY Dominant Dominated Reference
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Appendix 1
Calculation of treatment discontinuation 
relative risks
Treatment discontinuation relative risks were calculated for 
active treatment vs placebo using a 3-step method. First, 
patients who were terminated by the sponsor were removed 
from the efficacy sample, and the discontinuation rate due 
to relapse (or due to AE or other reasons) was recalculated 
for both the treatment and placebo groups. Of note, in the 
maintenance trial of cariprazine, no patients were terminated 
by the sponsor; therefore, this step was skipped for the 
 cariprazine calculation.11 Next, to ensure that all probabilities 
were calculated within the same time frame, any transition 
probabilities other than 6 months were converted by using 
the following formula where EXP refers to the exponential 
function and LN refers to the natural logarithm function: 
1-EXP(LN(1-Probability)/(Number of weeks in the original 
trial/26)). Finally, the 6-month probability from step 2 was 
adjusted by applying the relative risk method where the 
product between the relative clinical rate within trial (active 
vs respective placebo) and a pooled placebo clinical rate 
was calculated.
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